Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)
Arthritis Rheumatol. 2025 doi: 10.1002/art.43188 Epub ahead of print
Data from an international collaboration of registries show no evidence of an increase in CV events during the first 2 years of use with JAKi, compared to TNFi, in the general RA population.
With safety at the forefront of the use of JAK inhibitors, since the publication of ORAL Surveillance, Aymon, et al. aimed to assess the incidence of MACE, in this large multi-country real-world population study, in RA patients treated with JAKis, to that of alternative treatment options, such as TNFis and bDMARD-other mode of action, providing important long-term insights into the CV safety profile of these drugs.
Keywords:
